Linden Thomas Advisory Services LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Linden Thomas Advisory Services LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,607 shares of the biopharmaceutical company’s stock after purchasing an additional 136 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $2,290,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. FMR LLC lifted its position in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares during the period. Northern Trust Corp lifted its holdings in Regeneron Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after purchasing an additional 34,326 shares in the last quarter. Morgan Stanley lifted its holdings in Regeneron Pharmaceuticals by 2.7% during the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after purchasing an additional 25,792 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Regeneron Pharmaceuticals by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock valued at $796,142,000 after purchasing an additional 2,666 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in Regeneron Pharmaceuticals by 3.4% during the third quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock valued at $754,422,000 after purchasing an additional 30,050 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on REGN shares. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $8.00 during trading on Tuesday, hitting $908.16. The stock had a trading volume of 188,783 shares, compared to its average volume of 489,175. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The firm has a market capitalization of $99.68 billion, a P/E ratio of 25.90, a PEG ratio of 2.58 and a beta of 0.11. The company’s 50-day moving average price is $952.07 and its 200 day moving average price is $892.70. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $10.96 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,022 shares of company stock worth $10,552,991. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.